Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is a source of bicarbonate precursor. It is metabolized to bicarbonate in the liver, which buffers metabolic acidosis, restoring acid-base balance.
Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.
Alternative to sodium bicarbonate for metabolic acidosis when lactate metabolism is intact,Fluid and electrolyte replenishment,Mild to moderate metabolic acidosis
Source of electrolytes, calories, and water for hydration in patients with or without carbohydrate deficiency,Maintenance and replacement of fluid and electrolyte losses in pediatric patients,Treatment of hypophosphatemia,Off-label: Total parenteral nutrition component
Intravenous infusion: The typical adult dose is 300-500 m L of 1/6 Molar sodium lactate solution (approximately 167 m Eq/L each of sodium and lactate, 1 L contains 167 m Eq of sodium and lactate) administered as a continuous intravenous infusion at a rate of 0.5-2.5 m L/kg/hour, adjusted based on the severity of acidosis and clinical response. Maximum infusion rate: 2.5 m L/kg/hour.
Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.
30–60 minutes for lactate conversion; bicarbonate component determined by CO2 excretion.
Dextrose has a half-life of approximately 1.5–3 hours in patients with normal glucose metabolism; in renal failure, electrolyte half-lives may be prolonged. The half-life of sodium is about 2–4 hours, and potassium 2–6 hours, depending on renal function.
Primarily hepatic gluconeogenesis; lactate is converted to glucose via the Cori cycle, or oxidized to carbon dioxide and water; metabolism requires adequate liver function.
Dextrose is metabolized via glycolysis to pyruvate then enters the TCA cycle. Acetate is metabolized via TCA cycle to bicarbonate. Phosphate is excreted renally or incorporated into ATP and other compounds.
Primarily renal as bicarbonate and lactate; <5% unchanged.
Electrolytes are primarily excreted via renal pathways; dextrose is metabolized to CO2 and water, with negligible renal excretion. Specifically, sodium, potassium, magnesium, chloride, acetate, and gluconate are eliminated by the kidneys, with over 90% of infused electrolytes excreted renally.
Negligible (<1%); does not bind significantly to plasma proteins.
Sodium, potassium, chloride, magnesium, and acetate have negligible protein binding (<5%); calcium is ~45% bound to albumin; gluconate binding is minimal.
0.4-0.6 L/kg; distributes primarily in extracellular fluid.
Electrolytes distribute into total body water, approximately 0.6 L/kg for adults; dextrose distributes into extracellular fluid (~0.2 L/kg) but is rapidly taken up by cells.
Intravenous: 100%
Intravenous: 100% bioavailability.
Contraindicated in severe renal dysfunction (e GFR < 30 m L/min/1.73 m²) due to risk of hypernatremia and volume overload. In patients with e GFR 30-59 m L/min/1.73 m², use with caution, reduce infusion rate by 25-50%, and monitor serum sodium and fluid balance closely.
Contraindicated in severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload; for GFR 30-50 m L/min, use with caution and monitor potassium and fluid status.
Contraindicated in severe hepatic impairment (Child-Pugh Class C) due to impaired lactate metabolism. In Child-Pugh Class A or B, use with caution, reduce infusion rate by 50%, and monitor arterial blood gases and lactate levels frequently.
No specific dose adjustment for Child-Pugh class; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte imbalances.
Intravenous infusion: Administer 3-5 m L/kg of 1/6 Molar sodium lactate as a bolus over 30 minutes, followed by a continuous infusion at 0.5-1 m L/kg/hour, titrated to correct metabolic acidosis. Maximum infusion rate: 2 m L/kg/hour.
Intravenous infusion at a rate of 100-150 m L/kg/day for maintenance, adjusted based on weight, clinical condition, and electrolyte requirements.
Use with caution due to decreased renal function and higher risk of fluid overload. Start at lower end of dosing range (0.5-1 m L/kg/hour) and monitor serum electrolytes, fluid balance, and renal function closely. Contraindicated if e GFR < 30 m L/min/1.73 m².
Use with caution due to decreased renal function; start at lower infusion rates (e.g., 0.5-1 L per 24 hours) and monitor fluid and electrolyte status closely.
None.
Not for use in patients with intracranial or intraspinal hemorrhage, or in patients with known hypersensitivity to any component. Do not administer simultaneously with blood products through the same set due to risk of hemolysis.
Use with caution in patients with impaired liver function, lactic acidosis, or conditions predisposing to lactic acidosis (e.g., shock, hypoxia). Monitor serum electrolytes and acid-base status. Risk of hyperlactatemia if metabolism is impaired.
Risk of fluid overload, electrolyte disturbances, and hyperglycemia in patients with impaired renal function, cardiac failure, or diabetes,Use with caution in patients with severe hepatic disease (risk of lactic acidosis from acetate),Monitoring of serum electrolytes, glucose, fluid balance, and acid-base status is required,Avoid extravasation: risk of tissue necrosis
Severe lactic acidosis, hyperlactatemia, severe hepatic impairment, metabolic alkalosis, hypocalcemia, and patients with known hypersensitivity to sodium lactate.
Hyperkalemia, hypernatremia, hyperphosphatemia, hypocalcemia,Severe metabolic alkalosis or lactic acidosis,Anuria or severe oliguria,Addison's disease (risk of hyperkalemia),Known hypersensitivity to any component
No specific food interactions known. However, patients on sodium-restricted diets should account for the sodium content of this solution (approximately 167 m Eq/L).
No specific food interactions. Patients should maintain a balanced diet as tolerated, but sodium and potassium intake may need monitoring or adjustment based on electrolyte status. Avoid excessive ingestion of high-sodium or high-potassium foods unless directed by clinician.
Sodium lactate is a normal metabolic intermediate and component of IV fluids. No teratogenic effects are known at therapeutic doses. Risk cannot be ruled out in first trimester, but no specific fetal risks are associated with maternal administration of this physiologic compound.
Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential ions and do not pose fetal risk when administered appropriately. Hyperglycemia from excessive dextrose may be associated with fetal macrosomia, neonatal hypoglycemia, and other metabolic disturbances, particularly in diabetic pregnancies. No specific trimester risks are identified for isotonic balanced solutions.
Sodium lactate is a normal constituent of breast milk. Exogenous administration is unlikely to significantly alter milk levels. M/P ratio not established. Considered compatible with breastfeeding.
Dextrose and electrolytes are normal constituents of breast milk. Infusion of ISOLYTE H with 5% dextrose does not alter milk composition or supply significantly. No adverse effects on breastfed infants are anticipated. The M/P ratio is not applicable as these are endogenous substances; no accumulation expected.
No dose adjustment required. Physiologic increases in plasma volume during pregnancy may dilute infused fluids, but standard dosing based on clinical status is appropriate.
No specific dose adjustments for pregnancy; however, avoid excessive dextrose administration to prevent maternal hyperglycemia and fetal metabolic complications. Use with caution in gestational diabetes or preeclampsia; consider lower dextrose concentrations or rate adjustments based on maternal blood glucose and electrolyte levels.
Sodium lactate 1/6 Molar is a crystalloid solution providing approximately 167 m Eq/L of sodium and 167 m Eq/L of lactate. It is metabolized to bicarbonate in the liver, making it useful for correcting metabolic acidosis, especially in patients with lactic acidosis or those unable to tolerate bicarbonate due to hypocalcemia or hypercapnia. Monitor serum electrolytes, lactate levels, and acid-base status. Avoid in severe liver dysfunction as conversion to bicarbonate is impaired. Use with caution in patients with heart failure or renal impairment due to sodium load. For intravenous use only; do not administer with calcium-containing solutions due to precipitation risk.
ISOLYTE H with Dextrose 5% is a hypertonic solution (approx. 480 m Osm/L) used for fluid and electrolyte replacement in patients with hypochloremic metabolic alkalosis and fluid losses. It should be administered through a central line due to its high osmolarity. Monitor serum electrolytes, glucose, and acid-base status. Do not administer if solution is discolored or contains particulate matter.
This medication is a solution that helps correct acid buildup in your blood.,It will be given through a vein (intravenously) by a healthcare professional.,You may need frequent blood tests to monitor your electrolyte levels and acid-base balance.,Inform your doctor if you have liver disease, heart failure, or kidney problems.,Report any signs of fluid overload such as shortness of breath, swelling in the ankles or legs.,Do not take any other medications or supplements without consulting your doctor.,This solution contains sodium; discuss any dietary sodium restrictions with your healthcare provider.
This IV solution provides fluids, electrolytes, and calories to help correct imbalances caused by illness or surgery.,Tell your healthcare provider if you have a history of heart failure, kidney disease, or diabetes, as this solution may affect these conditions.,You may experience discomfort at the IV site; report any pain, redness, or swelling immediately.,Regular blood tests will be needed to monitor your electrolyte levels and kidney function.,Do not stop or adjust the infusion rate on your own.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER vs ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is a source of bicarbonate precursor. It is metabolized to bicarbonate in the liver, which buffers metabolic acidosis, restoring acid-base balance.. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Intravenous solution providing electrolytes (sodium, potassium, magnesium, chloride, acetate, phosphate) and dextrose for caloric supply. Acetate and phosphate serve as bicarbonate precursors to buffer metabolic acids. Dextrose provides energy and protein-sparing effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is: Intravenous infusion: The typical adult dose is 300-500 m L of 1/6 Molar sodium lactate solution (approximately 167 m Eq/L each of sodium and lactate, 1 L contains 167 m Eq of sodium and lactate) administered as a continuous intravenous infusion at a rate of 0.5-2.5 m L/kg/hour, adjusted based on the severity of acidosis and clinical response. Maximum infusion rate: 2.5 m L/kg/hour.. The standard adult dose of ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion, rate determined by patient's fluid and electrolyte needs; typical adult dose: 1-2 L per 24 hours, adjusted based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER and ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is classified as Category C. Sodium lactate is a normal metabolic intermediate and component of IV fluids. No teratogenic effects are known at therapeutic doses. Risk cannot be ruled out in first trimester, bu. ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose and electrolyte solutions are generally considered safe in pregnancy. Dextrose is a physiologic nutrient; no teratogenic effects are expected. Electrolytes are essential i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.